QHSLab (USAQ) 10-K 31 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	0-19041
Entity Registrant Name	USA EQUITIES CORP.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, Address Line Three	West Palm
Entity Address, City or Town	Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Title of 12(b) Security	Common Stock, $0.0001 Par Value
Trading Symbol	USAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float				$ 2,572,904
Entity Common Stock, Shares Outstanding			8,815,508
Auditor Name	Accell Audit & Compliance, P.A.	Cherry Bekaert LLP
Auditor Firm ID	3289	677
Auditor Location	Tampa, Florida	Tampa, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 286,855	$ 94,342
Accounts receivable	70,474	60,522
Inventory	65,740	99,701
Prepaid expenses and other current assets	22,713	11,598
Total current assets	445,782	266,163
Non-current assets:
Capitalized software development costs	186,271	31,700
Intangible assets, net	1,576,444
Total assets	2,208,497	297,863
Current Liabilities:
Accounts payable	20,370	145,422
Other current liabilities	58,615	14,198
Loans payable, current portion	253,865
Convertible notes payable, current portion	542,104
Convertible note payable, related party		55,000
Total current liabilities	874,954	214,620
Non-current liabilities:
Accrued interest expenses	6,521	115,566
Loans payable, non-current portion	402,956
Convertible notes payable	100,000	576,003
Total long-term liabilities	509,477	691,569
Total liabilities	1,384,431	906,189
Commitment and contingencies (Note 12)
Stockholders’ Equity (Deficit):
Common stock, 900,000,000 shares authorized, $0.0001 par value; 8,756,093 and 6,562,735 shares issued and outstanding at December 31, 2021 and 2020, respectively	876	656
Unearned stock compensation	(6,968)	(124,479)
Additional paid-in capital	3,348,681	1,264,108
Accumulated deficit	(2,518,895)	(1,748,719)
Total stockholders’ equity (deficit)	824,066	(608,326)
Total liabilities and stockholders’ equity (deficit)	2,208,497	297,863
Series A Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Preferred stock Series A-2, $0.0001 par value; 2,644,424 and 0 shares issued and outstanding at December 31, 2021 and 2020, respectively	108	108
Series A Two Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Preferred stock Series A-2, $0.0001 par value; 2,644,424 and 0 shares issued and outstanding at December 31, 2021 and 2020, respectively	$ 264

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.25
Common stock, shares authorized	900,000,000	900,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	8,756,093	6,562,735
Common stock, shares outstanding	8,756,093	6,562,735
Series A Preferred Stock [Member]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	1,080,092	1,080,092
Preferred stock, shares outstanding	1,080,092	1,080,092
Series A Two Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	2,644,424	0
Preferred stock, shares outstanding	2,644,424	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 1,414,421	$ 124,532
Cost of revenue	743,673	74,439
Gross profit	670,748	50,093
Operating Expenses:
Sales and marketing	592,068	95,141
General and administrative	454,008	131,767
Research and development	90,874	98,290
Amortization	36,056
Total Operating Expenses	1,173,006	325,198
Net operating loss	(502,258)	(275,105)
Interest expense	246,490	30,984
Loss on extinguishment of debt	21,428	21,299
Loss before income taxes	(770,176)	(327,388)
Provision on income taxes
Net loss	$ (770,176)	$ (327,388)
Basic and diluted net loss per share	$ (0.10)	$ (0.05)
Weighted average shares outstanding (basic and diluted)	7,861,077	6,200,303

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series A Two Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Unearned Stock Compensation [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 108			$ 576		$ 990,856	$ (1,421,331)	$ (429,791)
Beginning balance, shares at Dec. 31, 2019	1,080,092			5,762,735
Shares issued for services				$ 80	(266,250)	266,170
Shares issued for services, shares				800,000
Amortization of unearned compensation					141,771			141,771
Stock-based compensation expense						7,082		7,082
Net loss							(327,388)	(327,388)
Ending balance, value at Dec. 31, 2020	$ 108			$ 656	(124,479)	1,264,108	(1,748,719)	(608,326)
Ending balance, shares at Dec. 31, 2020	1,080,092			6,562,735
Stock-based compensation expense						35,683		35,683
Net loss							(770,176)	(770,176)
Warrants issued as deferred financing costs						221,779		221,779
Shares issued for services, net of cancellation				$ 12	(6,968)	81,288		74,332
Shares issued for services, net of cancellation, shares				120,000
Conversion of notes payable		$ 264		$ 84		802,019		802,367
Beginning balance, shares		2,644,424		837,213
Warrants issued with conversion of notes payable						21,428		21,428
Cancellation of shares				$ (10)		10
Cancellation of shares, shares				(100,000)
Amortization of unearned compensation					124,479			124,479
Shares issued for asset purchase				$ 125		862,375		862,500
Shares issued for asset purchase, shares				1,250,000
Share purchase				$ 5		29,995		30,000
Share purchase, shares				50,000
Shares issued in a funding				$ 4		29,996		30,000
Shares issued in a funding, shares				36,145
Ending balance, value at Dec. 31, 2021	$ 108	$ 264		$ 876	$ (6,968)	$ 3,348,681	$ (2,518,895)	$ 824,066
Ending balance, shares at Dec. 31, 2021	1,080,092	2,644,424		8,756,093

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net loss	$ (770,176)	$ (327,388)
Amortization	36,056
Amortization of debt and warrant issuance costs	153,883
Stock-based compensation	35,683	7,082
Shares issued for services	198,811	141,771
Loss on extinguishment of debt	21,428	21,299
Changes in net assets and liabilities:
Increase in accounts receivable	(9,952)	(60,522)
Decrease/(increase) in inventory	33,961	(99,701)
Decrease in prepaid expenses and other current assets	(11,115)	(8,848)
(Decrease)/increase in accounts payable	(125,052)	138,382
Increase/(decrease)/increase in other current liabilities	30,237	(7,656)
Decrease in accrued interest	51,498	30,017
Cash flows from operating activities	(354,738)	(165,564)
Investing activities:
Capitalized software	(154,571)	(31,700)
Cash flows from investing activities	(154,571)	(31,700)
Financing activities:
Proceeds from sales of common stock	30,000
Proceeds from convertible notes payable	850,000	180,000
Proceeds of loan borrowings	86,000
Repayments of loan borrowings	(179,178)
Payment of debt issuance costs	(85,000)
Proceeds of related party borrowings		88,016
Cash flows from financing activities	701,822	268,016
Change in cash	192,513	70,752
Cash and cash equivalents - beginning of year	94,342	23,590
Cash and cash equivalents - end of period	286,855	94,342
Supplemental disclosures of cash flow activity:
Cash paid for interest	43,023
Cash paid for income taxes
Non-cash investing and financing activity:
Long-term debt and accrued interest converted to shares of preferred stock	426,081
Debt and accrued interest converted to common stock	376,286
Debt and common stock issued for intangible assets (Note 4)	1,612,500
Common stock issued for debt issuance costs	30,000
Warrants issued in conjunction with convertible note payable	221,779
Conversion of due to related party to long-term debt		$ 88,016

The Company

The Company	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company USA Equities Corp. (the “Company”, or the “Registrant”) was incorporated in Delaware on September 1, 1983. In 2015, the Company changed its name to USA Equities Corp. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada as a result of a merger with and into its newly formed wholly-owned subsidiary, USA Equities Corp., a Nevada corporation (“USA Equities Nevada”), the surviving entity pursuant to an Agreement and Plan of Merger. The reincorporation was approved by the stockholders of the Company and USA Equities Nevada is deemed to be the successor to USA Equities Corp, the Delaware corporation.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, has negative operating cash flows and began recognizing revenues in the fourth quarter of fiscal 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon its ability to achieve profitability and positive cash flows and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Note 3. Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying audited consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. Reclassifications Certain reclassifications were made to the prior consolidated financial statements to conform to the current period presentation. There was no change to the previously reported net loss. Risks Related to COVID-19 Pandemic The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic could negatively impact the Company’s liquidity, capital resources and operations. The ultimate impact of the COVID-19 pandemic is highly uncertain and the Company does not yet know the full extent of potential impacts on its business, financing or global economy as a whole. Accounting Policies Use of Estimates : The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Principles of Consolidation Cash and Cash Equivalents Accounts Receivable : The Company extends unsecured credit to its customers on a regular basis. Management monitors the payments on outstanding balances and will establish a reserve for uncollectible balances as necessary based on experience. As of December 31, 2021 and 2020 there was no established reserve for uncollectible balances. Inventories : Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine our cost basis for inventories. Inventories consist of only finished goods. Provisions for excess and obsolete inventory are based on the Company’s estimates of forecasted sales, expiration dates and assumptions about obsolescence. As of December 31, 2021 and 2020 there was no established provisions for excess and obsolete inventory. Capitalized Software Development Costs : Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (“ASC”) 350-40, Intangibles, Internal-Use Software. Development costs that are incurred during the application development stage begin to be capitalized when two criteria are met: (i) the preliminary project stage is completed and (ii) it is probable that the software will be completed and used for its intended function. Capitalization ceases once the software is substantially complete and ready for its intended use. Costs incurred during the preliminary project stage of software development and post-implementation operating stages are expensed as incurred. Amortization is calculated on a straight-line basis over the remaining economic life of the software (typically three to five years) and will be included in operating expenses on the consolidated statements of operations once amortization begins. The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 186,271 as of December 31, 2021 and $ 31,700 as of December 31, 2020. The software application is still in development with costs continuing to be capitalized and no amortization expense being recognized during the years ended December 31, 2021 and December 31, 2020. There were no impairments recognized during the years ended December 31, 2021 and December 31, 2020. Intangible Assets: Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances may result in an impact to the value of the assets. Convertible Notes Payable: Derivatives and Hedging Debt with Conversion and Other Options Revenue Recognition Pursuant to ASC Topic 606, Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract. Research and Development 90,874 $ 98,290 , respectively Stock-based Compensation: Share Based Payment Earnings Per Common Share no Income Taxes Income Taxes, The Company has net operating losses of $ 2,518,895 which begin to expire in 2027 . Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization. Recently Issued Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU’) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)

Capitalized Software and Intang

Capitalized Software and Intangible Assets	12 Months Ended
	Dec. 31, 2021
Research and Development [Abstract]
Capitalized Software and Intangible Assets	Note 4. Capitalized Software and Intangible Assets Non-current assets consist of the following at December 31, 2021 and December 31, 2020: Schedule of Intangible Assets Estimated Useful Life December 31, 2021 December 31, Capitalized Software TBD $ 186,271 $ 31,700 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ - Web Domain N/A 161,250 - Trademark N/A 483,750 - Total Intangible Assets $ 1,612,500 $ - Accumulated amortization (36,056 ) - Intangible assets, net $ 1,576,444 $ - Capitalized software represents the development costs for internal-use software. The software application is still in development with costs continuing to be capitalized and no amortization expense being recognized yet. Capitalization will cease and amortization will begin once development is substantially complete. The Capitalized software costs will be amortized over the estimated life of the software. There were no impairments recognized during the years ended December 31, 2021 and December 31, 2020. The intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com” along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group as of June 23, 2021 for total consideration of $ 1,612,500 Business Combination, Related Issues, Initial Measurement. Intangibles, General Intangibles Other Than Goodwill 36,056 of amortization expense during the year ended December 31, 2021 and no amortization expense during the year ended December 31, 2020.

Loans Payable

Loans Payable	12 Months Ended
	Dec. 31, 2021
Loans Payable
Loans Payable	Note 5. Loans Payable On June 21, 2021, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 86,000 16,793 On June 23, 2021, the Company entered into a purchase agreement to acquire certain assets from MedScience Research Group, Inc (“MedScience”) (See Note 4 for additional information). As part of that purchase agreement, the Company issued a Promissory Note with a principal sum of $ 750,000 . The principal, along with associated interest, will be paid in 36 equal monthly installments beginning in July 2021. The principal balance of the loan is divided between current and long-term liabilities on the Company’s consolidated balance sheets. The combined principal due along with accrued interest as of December 31, 2021 is $ 644,158 .

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 6. Convertible Notes Payable Convertible notes payable at December 31, 2021 and December 31, 2020 consist of the following: Schedule of Convertible Notes Payable December 31, 2021 December 31, 2020 Note 1 and accrued interest and premium – Principal shareholder $ - $ 195,177 Note 2 and accrued interest – Principal shareholder - 126,210 Note 3 and accrued interest – Shareholder - 62,951 Note 4 and accrued interest – Principal shareholder - 97,537 Note 5 and accrued interest – Accredited investors - 56,462 Note 6 and accrued interest – Principal shareholder - 89,347 Note 7 and accrued interest – Accredited investors - 101,781 Note 8 and accrued interest – Accredited investors 27,555 25,055 Note 9 and accrued interest – Shareholder 106,521 - Note 10 and accrued interest, net of discount and issuance costs – Mercer Note 532,551 - Total Convertible notes payable and accrued interest $ 665,627 $ 754,520 Note 1 – In October 2009, the Company issued a Convertible Promissory Note with a principal amount of $ 73,500 to its principal shareholder (Note 1). The note bears interest at the rate of 12 % per annum until paid or the note and accrued interest is converted into shares of the Company’s common stock. On February 27, 2020, the note was modified to extend the maturity date to March 31, 2023 0.10 Debt, Modification and Extinguishments 21,299 On December 30, 2021, the Company and its principal shareholder entered into an agreement to exchange certain convertible promissory notes of the Company held by the principal shareholder along with associated accrued interest into 2,644,424 73,500 21,299 109,198 0.10 0 100,378 Note 2 – Effective September 1, 2019, the Company issued a Convertible Promissory Note in the principal amount of $ 124,562 1 0.25 On December 30, 2021, the Company and its principal shareholder entered into an agreement to exchange certain convertible promissory notes of the Company held by the principal shareholder along with associated accrued interest into 2,644,424 124,562 2,894 0.25 0 1,648 Note 3 – Effective September 12, 2019, the Company issued a Convertible Promissory Note in the principal amount of $ 55,000 12 0.25 55,000 7,951 0.25 251,805 Note 4 – Effective December 27, 2019, the Company issued a Convertible Promissory Note in the principal amount of $ 88,626 to its principal shareholder in consideration for advances previously made to the Company (Note 4). This note bore interest at the rate of 10 % per annum and was due and payable on December 30, 2022 . The Note was convertible into shares of common stock at a price of $ 0.55 per share. On March 15, 2021, the principal shareholder assigned this convertible note along with all accrued and future interest to a third-party shareholder. On March 31, 2021 the shareholder elected to convert the outstanding principal of $ 88,626 along with accrued interest of $ 11,096 into common stock at a price of $ 0.55 per share resulting in the issuance of 181,313 shares of common stock. As of December 31, 2021 and December 31, 2020, this note had accumulated $ 0 and $ 8,911 , respectively of accrued interest. Note 5 – Under subscription agreements dated September 25, 2020, the Company issued Convertible Promissory Notes (the “Notes”) to various individuals totaling $ 55,000 . The Notes bore interest at the rate of 10 % per annum and matured on September 30, 2022 (the “Maturity Date”) at which date all outstanding principal and accrued and unpaid interest are due and payable unless a Default Event, as defined, occurs. The Company could satisfy the Notes upon maturity or Default, as defined, by the issuance of Common shares at a conversion price equal to the greater of a 20% discount to the 15 day average market price of the Company’s common stock or $0.10. The principal and interest accrued are convertible at any time after six months through the Maturity Date at the option of the holder at a 20% discount to the 15 day average market price of the Company’s share price, but in no event less than $0.10 per share. Upon conversion of any portion of the Notes, the investor will receive warrants to purchase up to 25% of the number of common shares issued as a result of such conversion exercisable for a period of two years at a price per share equal to 150% of the conversion price of the Notes . As of March 16, 2021 one of the note holders had elected to convert outstanding principal of $ 30,000 along with accrued interest into 63,600 shares of common stock at a price of $ 0.50 . Additionally, the shareholder received warrants, exercisable for two years, to purchase 15,900 common shares at $ 0.75 per share. As of June 17, 2021 the other note holder had elected to convert outstanding principal of $ 25,000 48,755 0.55 12,189 0.83 As of December 31, 2021 and December 31, 2020, these notes had accumulated $ 0 1,462 Note 6 – Effective September 30, 2020, the Company issued a Convertible Promissory Note in the principal amount of $ 88,016 to its principal shareholder in consideration for advances previously made to the Company (Note 6). This note bears interest at the rate of 6 % per annum and is due and payable on December 31, 2022 . The Note is convertible into shares of common stock at a price of $ 1.00 per share. On December 30, 2021, the Company and its principal shareholder entered into an agreement to exchange certain convertible promissory notes of the Company held by the principal shareholder along with associated accrued interest into 2,644,424 of newly authorized Series A-2 Convertible Preferred Shares. Note 6 was included in that agreement with $ 88,016 of principal combined with accrued interest of $ 6,612 converted at $ 1.00 per share. As of December 31, 2021 and December 31, 2020, this note had accumulated $ 0 and $ 1,331 , respectively of accrued interest. Note 7 – Effective October 27, 2020, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 September 25, 2020 100,000 214,817 0.49 53,704 0.74 0 1,781 Note 8 – Effective December 23, 2020, the Company issued a Convertible Promissory Note in the principal amount of $ 25,000 September 25, 2020 2,555 55 Note 9 – Effective May 7, 2021, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 to a shareholder (Note 9). The Note bears interest at the rate of 10 % per annum and matures on September 30, 2022 (the “Maturity Date”) at which date all outstanding principal and accrued and unpaid interest are due and payable unless a Default Event, as defined, occurs. The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15 day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of September 30, 2022 at the option of the holder using the same conversion calculation. As of December 31, 2021, this note had accumulated $ 6,521 of accrued interest. Note 10 – Effective August 10, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which it issued to the investor an Original Issue Discount Secured Convertible Promissory Note (the “Note”) in the principal amount of $ 806,000 930,000 750,000 The principal amount of the Note and all interest accrued thereon is payable on August 10, 2022, and are secured by a lien on substantially all of the Company’s assets. The Note provides for interest at the rate of 5 0.65 0.65 0.65 Mercer Street Global Opportunity Fund, LLC, converted $ 50,000 806,000 76,923 0.65 The 930,000 1.25 The Company accounts for the allocation of its issuance costs to its Warrants in accordance with ASC 470-20, Debt with Conversion and Other Options. Under this guidance, if debt or stock is issued with detachable warrants, the proceeds need to be allocated to the two instruments using either the fair value method, the relative fair value method, or the residual value method. The Company used the relative fair value at the time of issuance to allocate the value received between the convertible note and the warrants. The Company estimated the fair value of warrants utilizing the Black-Scholes pricing model, which is dependent upon several assumptions such as the expected term of the Warrants, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants. The value allocated to the relative fair value of the Warrants was recorded as debt issuance costs and additional paid in capital. The principal, net of the original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, which are being recognized over the life of the note, along with associated interest, is recorded with current liabilities on the Company’s consolidated balance sheets. As of December 31, 2021, this note had accumulated $ 15,446 of accrued interest, total unamortized debt issuance costs of $ 204,835 , including the Warrant value, and the remaining discount of $ 34,060 .

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Preferred Stock	Note 7. Preferred Stock Issuance of Series A Preferred Stock Effective September 1, 2019, the Company issued 1,080,092 255,681 The shares of Series A Preferred Stock have a stated value of $ 0.25 0.05 The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote Issuance of Series A-2 Preferred Stock On December 30, 2021, the Board of Directors of the Company authorized the issuance of 2,644,424 286,078 The rights of holders of the Company’s common stock with respect to the payment of dividends and upon liquidation are junior in right of payment to holders of the Series A-2 Convertible Preferred Shares. The rights of the holders of the Company’s Series A-2 Preferred Shares are pari passu to the rights of the holders of the Company’s Series A Preferred Shares currently outstanding. Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company’s common stock and Series A Preferred Shares as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date.

Loss Per Common Share

Loss Per Common Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Loss Per Common Share	Note 8. Loss Per Common Share The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the years ended December 31, 2021 and 2020 as the result would be anti-dilutive. Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share Years Ended 2021 2020 Stock options 1,100,000 650,000 Stock warrants 1,019,793 - Total shares excluded from calculation 2,119,793 650,000

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Note 9. Stock-based Compensation During the years ended December 31, 2021 and 2020, there was $ 35,683 and $ 7,082 , respectively, in stock-based compensation associated with stock options included in research and development expense. Additionally, during the same periods there was $ 198,811 and $ 141,771 , respectively, of expense associated with shares issued for services. The following table shows where the expense has been recorded. Schedule of Stock-based Compensation Expenses Years Ended December 31, 2021 2020 Research and development $ 29,031 $ 57,469 Sales and marketing 98,331 60,219 General and administrative 71,449 24,083 Total expense – shares issued for services $ 198,811 $ 141,771 During the year ended December 31, 2021, there were 450,000 0.65 three years five years During the year ended , 2020, there were 650,000 0.40 three years five years As of December 31, 2021, there was $ 36,085 1,100,000 14 0.12 The fair value of all options granted is determined using the Black-Scholes option-pricing model. The following weighted-average assumptions were used: Schedule of Fair Value of Option Grant of Weighted-average Assumptions Year Ended Year Ended Risk-free interest rate 0.21 % 0.51 % Expected life of the options 3.5 3.5 Expected volatility of the underlying stock 76.3 % 70.7 % Expected dividend rate 0 % 0 % The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected term of the options. The expected life of the options is based on the option term. Due to the Company’s limited historical data, the expected volatility is calculated based upon the historical volatility of comparable companies whose share prices are publicly available for a sufficient period of time. The dividend rate is based on the Company never paying or having the intent to pay any cash dividends. On March 8, 2021, the Company entered into a Consulting Agreement (“Agreement 1”) with an Investor Relations Consultant, pursuant to which the Investor Relations Consultant was to provide investor relations services to the Company for consideration of 120,000 On March 10, 2021, the Company entered into a Consulting Agreement (“Agreement 2”) with a Legal Consultant to provide legal services to the Company for consideration of 30,000 16 On May 5, 2021, the Company entered into a Consulting Agreement (“Agreement 3”) with a Strategic Advisory Consultant to provide strategic and advisory services to the Company for consideration of 30,000 three months On June 14, 2021, the Company entered into a one-month Consulting Agreement (“Agreement 4”) with a Strategic Advisory Consultant to provide strategic and advisory services to the Company for consideration of 20,000 On July 16, 2021, the Company entered into a one-month Consulting Agreement (“Agreement 5”) with a Strategic Advisory Consultant to provide strategic and advisory services to the Company for consideration of 20,000 On August 16, 2021, the Company entered into a one-month Consulting Agreement (“Agreement 6”) with a Strategic Advisory Consultant to provide strategic and advisory services to the Company for consideration of 20,000 Options outstanding at December 31, 2021 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 12, 2020 500,000 333,333 $ 0.40 March 12, 2025 June 27, 2020 150,000 100,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 150,000 $ 0.65 December 31, 2025 Total 1,100,000 583,667 Warrants outstanding at December 31, 2021 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 16, 2021 15,900 15,900 $ 0.75 March 15, 2023 May 7, 2021 53,704 53,704 $ 0.74 May 6, 2023 June 17, 2021 12,189 12,189 $ 0.83 June 16, 2023 August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 Total 1,011,793 1,011,793

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	Note 10. Related-Party Transactions Convertible notes payable, related party: Issuance of Series A-2 Preferred Stock, related party:

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, The valuation allowance at December 31, 2021 and 2020 was $ 528,968 367,231 161,737 68,751 Reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for 2021 and 2020 are as follows: Schedule of Effective Income Tax Rate Reconciliation 2021 2020 For the Years Ended December 31, 2021 2020 Income tax at federal statutory rate 21.00 % 21.00 % Valuation allowance (21.00 )% (21.00 )% Income tax expense — — The Company has net operating losses of $ 2,518,895 begin to expire in 2027

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies On February 9, 2021, the Company entered into a Receivables Purchase and Security Agreement (“Factoring Agreement”) with a Factoring Company. The Factoring Agreement has an initial term of one year Under the terms of the agreement, designated receivables are sold for periodic advances of up to $ 150,000 10 1.8 As of December 31, 2021, the balance of outstanding invoices that the Factoring Company may assign back to the Company if not collected within 90 days is included in the Company’s Accounts Receivable balance with the amounts received, net of reserves held, included with other current liabilities on the consolidated balance sheets. The net amount included in other current liabilities is $ 25,420 There are no pending or threatened legal proceedings as of December 31, 2021. The Company has no non-cancellable operating leases.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Event	Note 13. Subsequent Event On February 23, 2022 the shareholder of convertible Note 8 listed in Note 6 elected to convert the outstanding principal of $ 25,000 59,415 0.47 two years 14,854 0.705 On March 2, 2022, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 123,000

Basis of Presentation (Policies

Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates : The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable : The Company extends unsecured credit to its customers on a regular basis. Management monitors the payments on outstanding balances and will establish a reserve for uncollectible balances as necessary based on experience. As of December 31, 2021 and 2020 there was no established reserve for uncollectible balances.
Inventories	Inventories : Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine our cost basis for inventories. Inventories consist of only finished goods. Provisions for excess and obsolete inventory are based on the Company’s estimates of forecasted sales, expiration dates and assumptions about obsolescence. As of December 31, 2021 and 2020 there was no established provisions for excess and obsolete inventory.
Capitalized Software Development Costs	Capitalized Software Development Costs : Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (“ASC”) 350-40, Intangibles, Internal-Use Software. Development costs that are incurred during the application development stage begin to be capitalized when two criteria are met: (i) the preliminary project stage is completed and (ii) it is probable that the software will be completed and used for its intended function. Capitalization ceases once the software is substantially complete and ready for its intended use. Costs incurred during the preliminary project stage of software development and post-implementation operating stages are expensed as incurred. Amortization is calculated on a straight-line basis over the remaining economic life of the software (typically three to five years) and will be included in operating expenses on the consolidated statements of operations once amortization begins. The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 186,271 as of December 31, 2021 and $ 31,700 as of December 31, 2020. The software application is still in development with costs continuing to be capitalized and no amortization expense being recognized during the years ended December 31, 2021 and December 31, 2020. There were no impairments recognized during the years ended December 31, 2021 and December 31, 2020. Intangible Assets: Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances may result in an impact to the value of the assets. Convertible Notes Payable: Derivatives and Hedging Debt with Conversion and Other Options
Revenue Recognition	Revenue Recognition Pursuant to ASC Topic 606, Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.
Research and Development	Research and Development 90,874 $ 98,290 , respectively Stock-based Compensation: Share Based Payment
Earnings Per Common Share	Earnings Per Common Share no
Income Taxes	Income Taxes Income Taxes, The Company has net operating losses of $ 2,518,895 which begin to expire in 2027 . Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU’) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life

Capitalized Software and Inta_2

Capitalized Software and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Research and Development [Abstract]
Schedule of Intangible Assets	Non-current assets consist of the following at December 31, 2021 and December 31, 2020: Schedule of Intangible Assets Estimated Useful Life December 31, 2021 December 31, Capitalized Software TBD $ 186,271 $ 31,700 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ - Web Domain N/A 161,250 - Trademark N/A 483,750 - Total Intangible Assets $ 1,612,500 $ - Accumulated amortization (36,056 ) - Intangible assets, net $ 1,576,444 $ -

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable at December 31, 2021 and December 31, 2020 consist of the following: Schedule of Convertible Notes Payable December 31, 2021 December 31, 2020 Note 1 and accrued interest and premium – Principal shareholder $ - $ 195,177 Note 2 and accrued interest – Principal shareholder - 126,210 Note 3 and accrued interest – Shareholder - 62,951 Note 4 and accrued interest – Principal shareholder - 97,537 Note 5 and accrued interest – Accredited investors - 56,462 Note 6 and accrued interest – Principal shareholder - 89,347 Note 7 and accrued interest – Accredited investors - 101,781 Note 8 and accrued interest – Accredited investors 27,555 25,055 Note 9 and accrued interest – Shareholder 106,521 - Note 10 and accrued interest, net of discount and issuance costs – Mercer Note 532,551 - Total Convertible notes payable and accrued interest $ 665,627 $ 754,520

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share	The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the years ended December 31, 2021 and 2020 as the result would be anti-dilutive. Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share Years Ended 2021 2020 Stock options 1,100,000 650,000 Stock warrants 1,019,793 - Total shares excluded from calculation 2,119,793 650,000

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expenses	Schedule of Stock-based Compensation Expenses Years Ended December 31, 2021 2020 Research and development $ 29,031 $ 57,469 Sales and marketing 98,331 60,219 General and administrative 71,449 24,083 Total expense – shares issued for services $ 198,811 $ 141,771
Schedule of Fair Value of Option Grant of Weighted-average Assumptions	The fair value of all options granted is determined using the Black-Scholes option-pricing model. The following weighted-average assumptions were used: Schedule of Fair Value of Option Grant of Weighted-average Assumptions Year Ended Year Ended Risk-free interest rate 0.21 % 0.51 % Expected life of the options 3.5 3.5 Expected volatility of the underlying stock 76.3 % 70.7 % Expected dividend rate 0 % 0 %
Schedule of Options Outstanding and Exercisable	Options outstanding at December 31, 2021 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 12, 2020 500,000 333,333 $ 0.40 March 12, 2025 June 27, 2020 150,000 100,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 150,000 $ 0.65 December 31, 2025 Total 1,100,000 583,667
Schedule of Warrants Outstanding and Exercisable	Warrants outstanding at December 31, 2021 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 16, 2021 15,900 15,900 $ 0.75 March 15, 2023 May 7, 2021 53,704 53,704 $ 0.74 May 6, 2023 June 17, 2021 12,189 12,189 $ 0.83 June 16, 2023 August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 Total 1,011,793 1,011,793

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for 2021 and 2020 are as follows: Schedule of Effective Income Tax Rate Reconciliation 2021 2020 For the Years Ended December 31, 2021 2020 Income tax at federal statutory rate 21.00 % 21.00 % Valuation allowance (21.00 )% (21.00 )% Income tax expense — —

Schedule of Indefinite-Lived In

Schedule of Indefinite-Lived Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2021
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Capitalized Software Development Costs for Software Sold to Customers	$ 186,271	$ 31,700
Capitalized Computer Software, Amortization	0	0
Capitalized Computer Software, Impairments	0	0
Research and development expense	$ 90,874	$ 98,290
Common stock equivalent shares of weighted average shares outstanding dilutive	2,119,793	650,000
Operating Loss Carryforwards	$ 2,518,895
Net operating losses carryforwards, expire date	begin to expire in 2027
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalent shares of weighted average shares outstanding dilutive	0	0

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 1,612,500
Accumulated amortization	(36,056)
Intangible assets, net	1,576,444
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	186,271	31,700
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 967,500
Finite-lived intangible assets, amortization method	13 years 4 months 24 days
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 161,250
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 483,750

Capitalized Software and Inta_3

Capitalized Software and Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Research and Development [Abstract]
Capitalized Computer Software, Impairments	$ 0	$ 0
Share issued	1,612,500
Depreciation, Depletion and Amortization	$ 36,056

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Jun. 23, 2021	Jun. 21, 2021	Dec. 31, 2021	Aug. 10, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance of debt		$ 86,000
Loans payable			$ 16,793
Debt Instrument, Face Amount				$ 806,000
Debt Instrument, Debt Default, Amount			$ 644,158
Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt Instrument, Face Amount	$ 750,000
Debt Instrument, Periodic Payment	$ 36

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	$ 665,627	$ 754,520
Convertible Notes Payable One [Member] | Principal Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		195,177
Convertible Notes Payable Two [Member] | Principal Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		126,210
Convertible Notes Payable Three [Member] | Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		62,951
Convertible Notes Payable Four [Member] | Principal Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		97,537
Convertible Notes Payable Five [Member] | Accredited Investor [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		56,462
Convertible Notes Payable Six [Member] | Principal Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		89,347
Convertible Notes Payable Seven [Member] | Accredited Investor [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest		101,781
Convertible Notes Payable Eight [Member] | Accredited Investor [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	27,555	25,055
Convertible Notes Payable Nine [Member] | Shareholder [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	106,521
Convertible Notes Payable Ten [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-term Debt [Line Items]
Total Convertible notes payable and accrued interest	$ 532,551

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)

Aug. 10, 2021

Aug. 10, 2021

May 07, 2021

Mar. 31, 2021

Mar. 16, 2021

Jan. 02, 2021

Dec. 31, 2020

Dec. 23, 2020

Oct. 27, 2020

Sep. 25, 2020

Feb. 27, 2020

Dec. 27, 2019

Mar. 31, 2021

Dec. 31, 2021

Aug. 10, 2022

Dec. 30, 2021

Nov. 15, 2021

Sep. 21, 2021

Jun. 17, 2021

Sep. 30, 2020

Sep. 12, 2019

Sep. 01, 2019

Oct. 31, 2009

Short-term Debt [Line Items]

Debt instrument face amount

$ 806,000

$ 806,000

Debt instrument convertible conversion price1

$ 0.65

$ 0.65

Stock issued during period shares conversion of convertible securities

76,923

Stock issued during period value conversion of convertible securities

$ 50,000

$ 802,367

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

204,835

Debt Instrument, Unamortized Discount

34,060

Convertible Notes Payable Nine [Member] | Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument, maturity date

Sep. 30, 2022

Accrued interest

6,521

Convertible Notes Payable Ten [Member] | Mercer Street Global Opportunity Fund LLC [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 806,000

$ 806,000

Warrants issued to purchase of common stock

930,000

930,000

Proceeds from warrant in consideration

$ 750,000

Convertible Promissory Note Ten [Member]

Short-term Debt [Line Items]

Debt instrument convertible conversion price1

$ 0.65

$ 0.65

Accrued interest

15,446

Warrants exercise price

$ 1.25

$ 1.25

Warrants exercised

930,000

930,000

Convertible Promissory Note Ten [Member] | Subsequent Event [Member]

Short-term Debt [Line Items]

Debt instrument interest rate stated percentage

5.00%

Debt instrument convertible conversion price1

$ 0.65

Accredited Investor [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 25,000

Debt instrument convertible conversion price1

$ 0.55

Accrued interest

$ 48,755

Warrants exercise price

$ 0.83

Warrants to purchase common stock

12,189

Convertible Notes Payable One [Member] | Principal Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 73,500

Debt instrument interest rate stated percentage

12.00%

Debt instrument, maturity date

Mar. 31, 2023

Debt instrument convertible conversion price1

$ 0.10

Extinguishment of Debt, Gain (Loss), Net of Tax

$ 21,299

Accrued interest

$ 100,378

0

Convertible Notes Payable One [Member] | Principal Shareholder [Member] | Series A 2 Convertible Preferred Shares [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 73,500

Debt instrument convertible conversion price1

$ 0.10

Interest payable current and noncurrent

$ 2,644,424

Debt instrument unamortized premium

21,299

Accrued interest

109,198

Convertible Notes Payable Two [Member] | Principal Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 124,562

Debt instrument interest rate stated percentage

1.00%

Debt instrument convertible conversion price1

$ 0.25

Accrued interest

1,648

0

Convertible Notes Payable Two [Member] | Principal Shareholder [Member] | Series A 2 Convertible Preferred Shares [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 124,562

Debt instrument convertible conversion price1

$ 0.25

Interest payable current and noncurrent

$ 2,894

Accrued interest

2,644,424

Convertible Notes Payable Three [Member] | Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 55,000

$ 55,000

Debt instrument interest rate stated percentage

12.00%

Debt instrument convertible conversion price1

$ 0.25

Accrued interest

$ 7,951

Common stock at a price

$ 0.25

Stock issued during period shares conversion of convertible securities

251,805

Convertible Notes Payable Four [Member] | Principal Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 88,626

$ 88,626

88,626

Debt instrument interest rate stated percentage

10.00%

Debt instrument, maturity date

Dec. 30, 2022

Debt instrument convertible conversion price1

$ 0.55

Accrued interest

$ 11,096

8,911

$ 11,096

0

Common stock at a price

$ 0.55

$ 0.55

Stock issued during period shares conversion of convertible securities

181,313

Convertible Notes Payable Five [Member] | Accredited Investor [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 30,000

$ 55,000

Debt instrument interest rate stated percentage

10.00%

Debt instrument, maturity date

Sep. 30, 2022

Debt instrument convertible conversion price1

$ 0.50

Accrued interest

$ 1,462

0

Stock issued during period shares conversion of convertible securities

63,600

Debt Instrument, Description

The Company could satisfy the Notes upon maturity or Default, as defined, by the issuance of Common shares at a conversion price equal to the greater of a 20% discount to the 15 day average market price of the Company’s common stock or $0.10. The principal and interest accrued are convertible at any time after six months through the Maturity Date at the option of the holder at a 20% discount to the 15 day average market price of the Company’s share price, but in no event less than $0.10 per share. Upon conversion of any portion of the Notes, the investor will receive warrants to purchase up to 25% of the number of common shares issued as a result of such conversion exercisable for a period of two years at a price per share equal to 150% of the conversion price of the Notes

Convertible Notes Payable Five [Member] | Accredited Investor [Member] | Warrant [Member]

Short-term Debt [Line Items]

Stock issued during period shares conversion of convertible securities

15,900

Warrants exercise price

$ 0.75

Convertible Notes Payable Six [Member] | Principal Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 88,016

Debt instrument interest rate stated percentage

6.00%

Debt instrument, maturity date

Dec. 31, 2022

Debt instrument convertible conversion price1

$ 1

Accrued interest

$ 1,331

0

Convertible Notes Payable Six [Member] | Principal Shareholder [Member] | Series A 2 Convertible Preferred Shares [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 88,016

Debt instrument convertible conversion price1

$ 1

Interest payable current and noncurrent

$ 6,612

Accrued interest

$ 2,644,424

Convertible Notes Payable Seven [Member] | Accredited Investor [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 100,000

$ 100,000

Debt instrument, maturity date

Sep. 25, 2020

Debt instrument convertible conversion price1

$ 0.49

Accrued interest

$ 214,817

1,781

0

Warrants exercise price

$ 0.74

Warrants to purchase common stock

53,704

Convertible Notes Payable Eight [Member] | Accredited Investor [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 25,000

Debt instrument, maturity date

Sep. 25, 2020

Accrued interest

$ 55

$ 2,555

Convertible Notes Payable Nine [Member] | Shareholder [Member]

Short-term Debt [Line Items]

Debt instrument face amount

$ 100,000

Debt instrument interest rate stated percentage

10.00%

Debt Instrument, Description

The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15 day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of September 30, 2022 at the option of the holder using the same conversion calculation. As of December 31, 2021, this note had accumulated $

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	Dec. 30, 2021	Aug. 10, 2021	Sep. 01, 2019	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Stock issued during period shares conversion of convertible securities		76,923
Debt instrument face amount		$ 806,000
Preferred stock stated value				$ 0.25
Debt instrument, conversion price		$ 0.65
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued during period shares conversion of convertible securities			1,080,092
Debt instrument face amount			$ 255,681
Preferred stock stated value				0.0001	$ 0.0001
Debt instrument, conversion price				$ 0.05
Preferred stock voting rights description				The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote
Series A 2 Convertible Preferred Shares [Member] | Board Of Directors [Member]
Class of Stock [Line Items]
Debt instrument face amount	$ 286,078
Stock issued during period value new issues	$ 2,644,424

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	2,119,793	650,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	1,100,000	650,000
Stock Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	1,019,793

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expenses (Details) - Shares Issued For Services [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services	$ 198,811	$ 141,771
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services	29,031	57,469
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services	98,331	60,219
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Expense - shares issued for services	$ 71,449	$ 24,083

Schedule of Fair Value of Optio

Schedule of Fair Value of Option Grant of Weighted-average Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.21%	0.51%
Expected life of the options	3 years 6 months	3 years 6 months
Expected volatility of the underlying stock	76.30%	70.70%
Expected dividend rate	0.00%	0.00%

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Mar. 12, 2020
Number Outstanding	500,000
Number Exercisable	333,333
Exercise Price | $ / shares	$ 0.40
Expiration Date	Mar. 12, 2025
Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Jun. 27, 2020
Number Outstanding	150,000
Number Exercisable	100,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Jun. 27, 2025
Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Jan. 1, 2021
Number Outstanding	450,000
Number Exercisable	150,000
Exercise Price | $ / shares	$ 0.65
Expiration Date	Dec. 31, 2025
Options Held [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding	1,100,000
Number Exercisable	583,667

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Warrant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Mar. 16, 2021
Number Outstanding	15,900
Number Exercisable	15,900
Exercise Price | $ / shares	$ 0.75
Expiration Date	Mar. 15, 2023
Warrant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	May 7, 2021
Number Outstanding	53,704
Number Exercisable	53,704
Exercise Price | $ / shares	$ 0.74
Expiration Date	May 6, 2023
Warrant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Jun. 17, 2021
Number Outstanding	12,189
Number Exercisable	12,189
Exercise Price | $ / shares	$ 0.83
Expiration Date	Jun. 16, 2023
Warrant Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date Issued	Aug. 10, 2021
Number Outstanding	930,000
Number Exercisable	930,000
Exercise Price | $ / shares	$ 1.25
Expiration Date	Aug. 9, 2024
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding	1,011,793
Number Exercisable	1,011,793

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative)	Aug. 16, 2021shares	Jul. 16, 2021shares	Jun. 14, 2021shares	May 05, 2021shares	Mar. 10, 2021shares	Mar. 08, 2021shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Share-based Payment Arrangement, Noncash Expense | $							$ 35,683	$ 7,082
Stock Issued During Period, Shares, New Issues							198,811	141,771
Unrecognized compensation related to unvested options | $							$ 36,085
Unrecognized compensation related to unvested options, shares							1,100,000
Recognized weighted-average period							14 months
Weighted-average fair value for options granted							0.12
Common Stock [Member] | Consulting Agreement One [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of common stock issued in consideration						120,000
Common Stock [Member] | Consulting Agreement Two [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of common stock issued in consideration					30,000
Agreement term period					16 months
Common Stock [Member] | Consulting Agreement Three [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of common stock issued in consideration				30,000
Agreement term period				3 months
Common Stock [Member] | Consulting Agreement Four [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of common stock issued in consideration			20,000
Common Stock [Member] | Consulting Agreement Five [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of common stock issued in consideration		20,000
Common Stock [Member] | Consulting Agreement Six [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of common stock issued in consideration	20,000
Scientific Advisors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of options granted							450,000	650,000
Weighted-average exercise price | $ / shares							$ 0.65	$ 0.40
Options vesting term							3 years	3 years
Options expiration period							5 years	5 years

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax at federal statutory rate	21.00%	21.00%
Valuation allowance	(21.00%)	(21.00%)
Income tax expense	0.00%	0.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Deferred tax assets, valuation allowance	$ 528,968	$ 367,231
Change in valuation allowance	161,737	$ 68,751
Operating losses carryforward	$ 2,518,895
Operating losses carryforward limitation on use	begin to expire in 2027

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 09, 2021	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current liabilities		$ 58,615	$ 14,198
Factoring Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement term	1 year
Advances on sale on receivables	$ 150,000
Reserve of purchased receivables, percentage	10.00%
Factoring fees, percentage	1.80%
Other current liabilities		$ 25,420

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($)	Mar. 02, 2022	Feb. 23, 2022	Aug. 10, 2021
Subsequent Event [Line Items]
Debt instrument, principal amount			$ 806,000
Common stock conversion price			$ 0.65
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceed from loan	$ 123,000
Subsequent Event [Member] | Convertible Note [Member] | Shareholder [Member]
Subsequent Event [Line Items]
Debt instrument, principal amount		$ 25,000
Number of shares convertible		59,415
Common stock conversion price		$ 0.47
Warrant term		2 years
Purchase of warrant		14,854
Warrant price per share		$ 0.705